The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a
serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of …

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of
patients with hepatocellular carcinoma (HCC). Following the positive results of the …

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) remains a serious
challenge due to high heterogeneity and limited treatment options. In the past few decades …

The global burden of hepatocellular carcinoma (HCC), one of the frequent causes of cancer-
related deaths worldwide, is rapidly increasing partly due to the limited treatment options …

Hepatocellular carcinoma (HCC) is among the most frequent and deadly human cancers
worldwide. It has been shown that interaction between immune checkpoint receptors and …

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative
approach in treating advanced hepatocellular carcinoma (HCC). Despite their success …

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …